Heart Center, Kuopio University Hospital, Kuopio, Finland; Department of Surgery, Jyväskylä Central Hospital, Jyväskylä, Finland.
Department of Surgery, Jyväskylä Central Hospital, Jyväskylä, Finland; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
J Vasc Surg. 2022 Oct;76(4):908-915.e2. doi: 10.1016/j.jvs.2022.03.859. Epub 2022 Mar 31.
This study evaluated radiographically quantified sarcopenia and the patient's comorbidity burden based on traditional cardiovascular risk assessment as potential predictors of long-term mortality after endovascular aortic repair (EVAR).
The study included 480 patients treated with standard EVAR for intact infrarenal abdominal aortic aneurysms. Patient characteristics, comorbidities, aneurysm dimensions, and other preoperative risk factors were collected retrospectively. Preoperative computed tomography was used to measure psoas muscle area (PMA) at the L3 level. Patients were divided into three groups based on American Society of Anesthesiologists (ASA) score and PMA. In the high-risk group, patients had sarcopenia (PMA <8.0 cm for males and <5.5 cm for females) and an ASA score of 4. In the medium-risk group, patients had either sarcopenia or an ASA score of 4. Patients in the low-risk group had no sarcopenia and the ASA score was less than 4. Risk factors for long-term mortality were determined using multivariable analysis. Kaplan-Meier survival estimates were calculated for all-cause mortality.
Patients in the high- and medium-risk groups were older than those in the low-risk group (77 ± 7, 76 ± 6, and 74 ± 8 years, respectively, P < .01). Patients in the high-risk group had higher prevalence of coronary artery disease, pulmonary disease, and chronic kidney disease. There were no differences in 30-day or 90-day mortality between the groups. The independent predictors of long-term mortality were age, ASA score, PMA, chronic kidney disease, and maximum aneurysm sac diameter. The estimated 1-year mortality rates were 5% ± 2% for the low-risk, 5% ± 2% for the medium-risk, and 18% ± 5% for the high-risk group (P < .01). Five-year mortality estimates were 23% ± 4%, 36% ± 3%, and 60% ± 6%, respectively (P < .01). The mean follow-up time was 5.0 ± 2.8 years.
Both ASA and PMA were strong predictors of increased mortality after elective EVAR. The combination of these two can be used as a simple risk stratification tool to identify patients in whom aneurysm repair or the intensive long-term surveillance after EVAR may be unwarranted.
本研究旨在评估基于传统心血管风险评估的影像学量化的肌肉减少症和患者的合并症负担,作为血管内修复(EVAR)后长期死亡率的潜在预测因素。
本研究纳入了 480 例接受标准 EVAR 治疗的完整肾下腹主动脉瘤患者。回顾性收集患者特征、合并症、瘤体尺寸和其他术前危险因素。术前 CT 用于测量 L3 水平的竖脊肌面积(PMA)。根据美国麻醉医师协会(ASA)评分和 PMA 将患者分为三组。高危组患者有肌肉减少症(男性 PMA<8.0cm,女性 PMA<5.5cm)和 ASA 评分 4 分。中危组患者要么有肌肉减少症,要么有 ASA 评分 4 分。低危组患者无肌肉减少症,ASA 评分<4 分。使用多变量分析确定长期死亡率的危险因素。计算所有原因死亡率的 Kaplan-Meier 生存估计。
高危组和中危组患者的年龄均大于低危组(分别为 77±7、76±6 和 74±8 岁,P<0.01)。高危组患者更常见的合并症包括冠状动脉疾病、肺部疾病和慢性肾脏病。各组之间 30 天或 90 天死亡率无差异。长期死亡率的独立预测因素是年龄、ASA 评分、PMA、慢性肾脏病和最大瘤囊直径。估计的 1 年死亡率分别为低危组 5%±2%、中危组 5%±2%和高危组 18%±5%(P<0.01)。5 年死亡率估计分别为 23%±4%、36%±3%和 60%±6%(P<0.01)。平均随访时间为 5.0±2.8 年。
ASA 和 PMA 都是 EVAR 后死亡率增加的有力预测因素。这两种方法的结合可以作为一种简单的风险分层工具,以识别可能不需要进行动脉瘤修复或 EVAR 后强化长期监测的患者。